Logo image of SWTX

SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SWTX - US85205L1070 - Common Stock

46.99 USD
+0.01 (+0.02%)
Last: 6/30/2025, 8:00:01 PM
46.98 USD
-0.01 (-0.02%)
After Hours: 6/30/2025, 8:00:01 PM
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to SWTX. SWTX was compared to 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SWTX as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, SWTX is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • SWTX had negative earnings in the past year.
  • SWTX had a negative operating cash flow in the past year.
  • SWTX had negative earnings in each of the past 5 years.
  • SWTX had a negative operating cash flow in each of the past 5 years.
SWTX Yearly Net Income VS EBIT VS OCF VS FCFSWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

  • With a Return On Assets value of -50.25%, SWTX perfoms like the industry average, outperforming 49.64% of the companies in the same industry.
  • SWTX has a better Return On Equity (-60.84%) than 60.14% of its industry peers.
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROIC N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
SWTX Yearly ROA, ROE, ROICSWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

  • The Gross Margin of SWTX (93.23%) is better than 94.31% of its industry peers.
  • The Profit Margin and Operating Margin are not available for SWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SWTX Yearly Profit, Operating, Gross MarginsSWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

  • SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, SWTX has more shares outstanding
  • SWTX has more shares outstanding than it did 5 years ago.
  • SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SWTX Yearly Shares OutstandingSWTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SWTX Yearly Total Debt VS Total AssetsSWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • SWTX has an Altman-Z score of 20.07. This indicates that SWTX is financially healthy and has little risk of bankruptcy at the moment.
  • With an excellent Altman-Z score value of 20.07, SWTX belongs to the best of the industry, outperforming 93.59% of the companies in the same industry.
  • There is no outstanding debt for SWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.07
ROIC/WACCN/A
WACC9.79%
SWTX Yearly LT Debt VS Equity VS FCFSWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

  • SWTX has a Current Ratio of 4.33. This indicates that SWTX is financially healthy and has no problem in meeting its short term obligations.
  • SWTX's Current ratio of 4.33 is in line compared to the rest of the industry. SWTX outperforms 49.11% of its industry peers.
  • SWTX has a Quick Ratio of 4.18. This indicates that SWTX is financially healthy and has no problem in meeting its short term obligations.
  • SWTX's Quick ratio of 4.18 is in line compared to the rest of the industry. SWTX outperforms 49.47% of its industry peers.
Industry RankSector Rank
Current Ratio 4.33
Quick Ratio 4.18
SWTX Yearly Current Assets VS Current LiabilitesSWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 33.79% over the past year.
  • SWTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 730.42%.
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.73% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 40.44% on average over the next years. This is a very strong growth
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%

3.3 Evolution

SWTX Yearly Revenue VS EstimatesSWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SWTX Yearly EPS VS EstimatesSWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SWTX. In the last year negative earnings were reported.
  • Also next year SWTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SWTX Price Earnings VS Forward Price EarningsSWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SWTX Per share dataSWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SWTX's earnings are expected to grow with 32.89% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.17%
EPS Next 3Y32.89%

More info and screens

0

5. Dividend

5.1 Amount

  • SWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRINGWORKS THERAPEUTICS INC

NASDAQ:SWTX (6/30/2025, 8:00:01 PM)

After market: 46.98 -0.01 (-0.02%)

46.99

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09
Earnings (Next)08-05
Inst Owners85.23%
Inst Owner Change-6.35%
Ins Owners1.38%
Ins Owner Change0%
Market Cap3.54B
Revenue(TTM)219.67M
Net Income(TTM)-253.93M
Analysts50.91
Price Target53.33 (13.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.05%
Min EPS beat(2)-44.63%
Max EPS beat(2)-35.47%
EPS beat(4)2
Avg EPS beat(4)-5.34%
Min EPS beat(4)-44.63%
Max EPS beat(4)52.52%
EPS beat(8)5
Avg EPS beat(8)-3.18%
EPS beat(12)7
Avg EPS beat(12)-2.43%
EPS beat(16)7
Avg EPS beat(16)-7.99%
Revenue beat(2)1
Avg Revenue beat(2)-12.64%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)9.03%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)70.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.25%
EPS NY rev (1m)-7.21%
EPS NY rev (3m)-15.2%
Revenue NQ rev (1m)-3.51%
Revenue NQ rev (3m)-4.74%
Revenue NY rev (1m)-2.75%
Revenue NY rev (3m)-6.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.11
P/FCF N/A
P/OCF N/A
P/B 8.48
P/tB 8.48
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS2.92
BVpS5.54
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.23%
FCFM N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 524.84%
Cap/Sales 9.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.33
Quick Ratio 4.18
Altman-Z 20.07
F-Score6
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)788.2%
Cap/Depr(5y)591.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%
EBIT growth 1Y26.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.3%
OCF growth 3YN/A
OCF growth 5YN/A

SPRINGWORKS THERAPEUTICS INC / SWTX FAQ

Can you provide the ChartMill fundamental rating for SPRINGWORKS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SWTX.


What is the valuation status of SPRINGWORKS THERAPEUTICS INC (SWTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to SPRINGWORKS THERAPEUTICS INC (SWTX). This can be considered as Overvalued.


Can you provide the profitability details for SPRINGWORKS THERAPEUTICS INC?

SPRINGWORKS THERAPEUTICS INC (SWTX) has a profitability rating of 1 / 10.